FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, June 6, 2023 -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant prostate cancer (mCRPC).
The approval was based on findings from the PROpel trial in which 796 patients with mCRPC were randomly assigned (1:1) to receive either Lynparza with abiraterone or placebo with abiraterone and also received prednisone or prednisolone. According to the results of the study, there was a statistically significant improvement in investigator-assessed radiological progression-free survival for Lynparza with abiraterone versus placebo with abiraterone. A subgroup analysis suggested that improvement in radiological progression-free survival was driven by patients with BRCA-mutated cancer. Lynparza was approved with a companion diagnostic test to assess BRCA mutational status.
For patients taking Lynparza, the most common adverse reactions included anemia (48 percent), fatigue (38 percent), nausea (30 percent), diarrhea (19 percent), decreased appetite (16 percent), lymphopenia (14 percent), dizziness (14 percent), and abdominal pain (13 percent). Nearly one in five patients (18 percent) required at least one blood transfusion.
Approval of Lynparza was granted to AstraZeneca.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Urine Test Might Help Men Skip Prostate Biopsies
THURSDAY, April 18, 2024 -- When prostate cancer strikes, one question is paramount: Is it aggressive and requiring immediate treatment, or slow-growing and worthy of monitoring...
Helping Poorer Patients Pay for Prostate Cancer Meds Keeps Them on Treatment
MONDAY, March 25, 2024 — Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than...
Ultrasound Plus MRI Could Be New Treatment Strategy Against Prostate Cancer
WEDNESDAY, March 20, 2024 -- Precisely delivered ultrasound could be an effective treatment for prostate cancer, with high-frequency sound waves heating and killing off cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
